Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Operating Expenses (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Operating Expenses readings, the most recent being $3.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 46.56% year-over-year to $3.2 million, compared with a TTM value of $18.4 million through Dec 2025, down 21.49%, and an annual FY2025 reading of $18.4 million, down 21.49% over the prior year.
  • Operating Expenses hit $3.2 million in Q4 2025 for Lisata Therapeutics, down from $4.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $6.9 million in Q2 2023, with the low at $3.2 million in Q4 2025.
  • Median Operating Expenses over the past 3 years was $5.9 million (2024), compared with a mean of $5.6 million.
  • The sharpest move saw Operating Expenses fell 1.26% in 2024, then tumbled 46.56% in 2025.
  • Year by year, Operating Expenses stood at $6.0 million in 2023, then fell by 1.26% to $5.9 million in 2024, then crashed by 46.56% to $3.2 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $3.2 million, $4.4 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.